Targets Validation

  • Two possible senarios could be expected after primary/secondary siRNAs screening. If the generated targets are known for cancer therapy but not applied in such indication of CRCs, new indication for existing targets are expected to be developed, while if a purely novel target is discovered, following validation in both in vitro using such CRCs and in vivo using corresponding PDX models can be done to further characterize the profiles of the potential target.

Targets Validation_LIDE Biotech